Evidence map›Paper›PMID 38966771›Full record

ArticleIJU case reports2024

Preoperative oral treatment with cyclooxygenase-2 inhibitor for cystitis glandularis.

Masato Yanagi, Norio Motoda, Akifumi Katsu, Hiroyoshi Kono, Ryoji Kimata, Tsutomu Hamasaki, Yukihiro Kondo

Abstract readCase Reports
In one paragraph

Article in IJU case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masato YanagiDepartment of Urology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.ORCID https://orcid.org/0000-0003-3092-1014
Norio MotodaDepartment of Pathology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.
Akifumi KatsuDepartment of Urology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.
Hiroyoshi KonoDepartment of Urology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.
Ryoji KimataDepartment of Urology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.
Tsutomu HamasakiDepartment of Urology Nippon Medical School Musashikosugi Hospital Kawasaki Kanagawa Japan.
Yukihiro KondoDepartment of Urology Nippon Medical School Hospital Bunkyo-ku Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A previous report has shown that cyclooxygenase-2 inhibitors can prevent the recurrence of cystitis glandularis postoperatively. Herein, we present a case of cystitis glandularis in which the tumor volume was markedly reduced by preoperative oral administration of a cyclooxygenase-2 inhibitor. Case presentation: A 45-year-old man with voiding difficulty and lower abdominal pain during urination was referred to our hospital. Cystoscopy revealed multiple cystitis glandularis-like edematous masses on the trigone and the neck of the bladder, completely involving the bilateral ureteral orifices. Cyclooxygenase-2 inhibitor was orally administered at the patient's request. Six weeks later, the tumor volume was markedly reduced, bilateral ureteral orifices were identified, and the voiding difficulty and pain on urination disappeared. Complete transurethral resection of the residual tumor was performed, and the pathological diagnosis was intestinal-type cystitis glandularis. Conclusion: Cyclooxygenase-2 inhibition can be considered a useful therapeutic strategy for cystitis glandularis.

Indexed as

bladder tumorcyclooxygenase‐2 inhibitorcystitis glandularispreoperativeureteral orifice

Identifiers

PMID38966771
PMCPMC11221942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.